Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...
Meet our Team at booth #624 during ASGCT 26th Annual Meeting, in Los Angeles, California, May 16th -20th, 2023. Don't miss the opportunity to hear from Polyplus and Exothera on High-performance, scalable process for cost-effective AAV manufacturing and The technical tool on FectoVIR®-LV. Check out our Poster Development of a novel helper plasmid: one step closer to the next generation rAAV vectors.
Talk: Introducing FectoVIR®-LV, next-generation transfection reagent for of large scale therapeutic lentivirus production. Wednesday May 17, 2023: 04:30 PM – 04:45 PM PT
Mathieu Porte Ph.D., R&D Manager Bioproduction at Polyplus®.
Talk: High-performance, scalable process for cost-effective AAV manufacturing. Wednesday May 18, 2023: 09:15 AM – 09:45 AM PT
A case study of transfer from bench-scale to 1000L, presented by Polyplus and Exothera
Géraldine Guérin- Peyrou Ph.D. , Director of Marketing & Technical Support at Polyplus ®.
Hanna P. Lesch Ph.D., CTO of Exothera.
Development of a novel helper plasmid: one step closer to the next generation rAAV vectors. [Board No. 1509]
Eric Mauro, Jonathan Havard, Sylvain Julien, Laure Robert, Carine Morel, Patrick Erbacher
Harnessing rAAVs as viral vectors for therapeutic transgene delivery still requires improvements in yields and specificity to lower vector doses, and therefore manufacturing cost, as well as to improve patient safety. To this end, our research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV particles using transient transfection, as well as enhancing features of rAAV vectors that act on the overall size of packaged material and specificity of delivery. Here we present our state-of-the art approach to design new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle obtained from suspension cultures. We took the opportunity to exploit our proprietary DNA assembly method technology to explore the synergies of multiple genetic features modularly assembled in synthetic plasmids. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions. Our expertise in DNA plasmid design and assembly together with our scalable transfection solutions for rAAV manufacturing gives us the potential to improve both productivity and specificity of gene therapy products. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions.